Skip to main content

Cerevel Therapeutics Hldg Inc(CERE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

Globe Newswire - Thu Dec 16, 2021

CAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today announced a phased multi-year, joint research collaboration in neuropsychiatry. The collaboration integrates the deep expertise in neuroscience drug discovery at Cerevel Therapeutics with state-of-the-art disease models and the AI-enabled deep phenotyping from Herophilus.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe